Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast

Journal of Breast Cancer

Volumn 18, Issue 1, 2015, Pages 1-7

  Kim, Hyunsung ^a   Jang, Se Min ^a   Ahn, Hyein ^a   Sim, Jongmin ^a   Yi, Kijong ^a   Chung, Yumin ^a   Han, Hulin ^a   Rehman, Abdul ^a   Chung, Min Sung ^a   Jang, Kiseok ^a   Paik, Seung Sam ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Dual specificity phosphatase 4; Prognosis

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PEROXIDASE; PHOSPHATASE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

EID: 84925959931     PISSN: 17386756     EISSN: 20929900     Source Type: Journal    
DOI: 10.4048/jbc.2015.18.1.1     Document Type: Article

References (18)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-418.
2. Schmidt M, Voelker HU, Kapp M, Krockenberger M, Dietl J, Kammer-er U. Glycolytic phenotype in breast cancer: activation of Akt, up-regu-lation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 2010;136:219-225.
3. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 2010;10:955-960.
4. Jang SM, Han H, Jang KS, Jun YJ, Jang SH, Min KW, et al. The glycolytic phenotype is correlated with aggressiveness and poor prognosis in invasive ductal carcinomas. J Breast Cancer 2012;15:172-180.
5. Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 2008;130: 414-424.
6. Gröschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hof-städter F, et al. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer 2013;132:1537-1546.
7. De Vriendt V, De Roock W, Di Narzo AF, Tian S, Biesmans B, Jacobs B, et al. DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers 2013;18:516-524.
8. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Okugawa Y, Shimura T, et al. Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. Med Oncol 2013;30:620.
9. Liu Y, Du F, Chen W, Yao M, Lv K, Fu P. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ ADR breast cancer cells to doxorubicin. Exp Cell Res 2013;319:3140-3149.
10. Jang SM, Sim J, Han H, Ahn HI, Kim H, Yi K, et al. Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast. J Clin Pathol 2013;66:681-686.
11. Jang SM, Han H, Jun YJ, Jang SH, Min KW, Sim J, et al. Clinicopathological significance of CADM4 expression, and its correlation with expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J Clin Pathol 2012;65:902-906.
12. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, et al. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 2010;70:1689-1699.
13. Armes JE, Hammet F, de Silva M, Ciciulla J, Ramus SJ, Soo WK, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004;23:5697-5702.
14. Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, et al. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast Cancer Res Treat 2014;148:211-220.
15. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191:229-237.
16. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 2010;49:1024-1034.
17. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001;280: 992-997.
18. Teutschbein J, Haydn JM, Samans B, Krause M, Eilers M, Schartl M, et al. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer 2010;10:386.